ImmunologyChronic DiseasesRespiratoryInflammationVaccinesInfectious DiseasesCentral Nervous SystemOncologyConsumerHealth CarePharmaceuticalVenture Capital
Description
GSK plc (GSK) operates as a global biopharma company. The company discovers, develops and delivers medicines and vaccines to create value for patients.
GSK focuses on the science of the immune system and advanced technologies, investing in four core…
Analysis
Bargain bin
GSK plc is priced cheaply, and that invites the natural question of why, since the underlying business scores below average. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is attractive. The owner-earnings multiple stands at 13.0×; owner earnings: the cash an owner could take out each year. The implied growth embedded in that price is around 0% a year, against analyst forecasts of 6%. The price, in other words, assumes less than the experts do.
Growth is moderate; the safety picture is adequate. The company scores 18/20 on our value-creation score: strong value creator.
Flags to be aware of: The financial cushion is thinner than comfortable. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202314
54
2023202420252026
All-time high
72
Nov 2023
All-time low
4
Jan 2026
Average rank
29
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
64
50
67
85
Price/Earnings
67
91
89
87
Price/Book
45
20
26
34
Dividend Yield
91
90
90
96
Value (overall)
85
80
70
83
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.